Myeloproliferative Neoplasms, Version 3.2022

Aaron T. Gerds; Jason Gotlib; Haris Ali; Prithviraj Bose; Andrew Dunbar; Amro Elshoury; Tracy I. George; Krishna Gundabolu; Elizabeth Hexner; Gabriela S. Hobbs; Tania Jain; Catriona Jamieson; Paul R. Kaesberg; Andrew T. Kuykendall; Yazan Madanat; Brandon McMahon; Sanjay R. Mohan; Kalyan V. Nadiminti; Stephen Oh; Animesh Pardanani; Nikolai Podoltsev; Lindsay Rein; Rachel Salit; Brady L. Stein; Moshe Talpaz; Pankit Vachhani; Martha Wadleigh; Sarah Wall; Dawn C. Ward; Mary Anne Bergman; Cindy Hochstetler

doi:10.6004/jnccn.2022.0046

Myeloproliferative Neoplasms, Version 3.2022

Aaron T. Gerds, Jason Gotlib, Haris Ali, Prithviraj Bose, Andrew Dunbar, Amro Elshoury, Tracy I. George, Krishna Gundabolu, Elizabeth Hexner, Gabriela S. Hobbs, Tania Jain, Catriona Jamieson, Paul R. Kaesberg, Andrew T. Kuykendall, Yazan Madanat, Brandon McMahon, Sanjay R. Mohan, Kalyan V. Nadiminti, Stephen Oh, Animesh PardananiNikolai Podoltsev, Lindsay Rein, Rachel Salit, Brady L. Stein, Moshe Talpaz, Pankit Vachhani, Martha Wadleigh, Sarah Wall, Dawn C. Ward, Mary Anne Bergman, Cindy Hochstetler

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

The classic Philadelphia chromosome-negativemyeloproliferative neoplasms (MPN) consist ofmyelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for themanagement of MPN in adults. TheGuidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.

Original language	English (US)
Pages (from-to)	1033-1062
Number of pages	30
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	20
Issue number	9
DOIs	https://doi.org/10.6004/jnccn.2022.0046
State	Published - Sep 2022

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2022.0046

Cite this

Gerds, A. T., Gotlib, J., Ali, H., Bose, P., Dunbar, A., Elshoury, A., George, T. I., Gundabolu, K., Hexner, E., Hobbs, G. S., Jain, T., Jamieson, C., Kaesberg, P. R., Kuykendall, A. T., Madanat, Y., McMahon, B., Mohan, S. R., Nadiminti, K. V., Oh, S., ... Hochstetler, C. (2022). Myeloproliferative Neoplasms, Version 3.2022. JNCCN Journal of the National Comprehensive Cancer Network, 20(9), 1033-1062. https://doi.org/10.6004/jnccn.2022.0046

Gerds, AT, Gotlib, J, Ali, H, Bose, P, Dunbar, A, Elshoury, A, George, TI, Gundabolu, K, Hexner, E, Hobbs, GS, Jain, T, Jamieson, C, Kaesberg, PR, Kuykendall, AT, Madanat, Y, McMahon, B, Mohan, SR, Nadiminti, KV, Oh, S, Pardanani, A, Podoltsev, N, Rein, L, Salit, R, Stein, BL, Talpaz, M, Vachhani, P, Wadleigh, M, Wall, S, Ward, DC, Bergman, MA & Hochstetler, C 2022, 'Myeloproliferative Neoplasms, Version 3.2022', JNCCN Journal of the National Comprehensive Cancer Network, vol. 20, no. 9, pp. 1033-1062. https://doi.org/10.6004/jnccn.2022.0046

@article{80dd9a101b514cd596b3deaf7edb014c,

title = "Myeloproliferative Neoplasms, Version 3.2022",

abstract = "The classic Philadelphia chromosome-negativemyeloproliferative neoplasms (MPN) consist ofmyelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for themanagement of MPN in adults. TheGuidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.",

author = "Gerds, {Aaron T.} and Jason Gotlib and Haris Ali and Prithviraj Bose and Andrew Dunbar and Amro Elshoury and George, {Tracy I.} and Krishna Gundabolu and Elizabeth Hexner and Hobbs, {Gabriela S.} and Tania Jain and Catriona Jamieson and Kaesberg, {Paul R.} and Kuykendall, {Andrew T.} and Yazan Madanat and Brandon McMahon and Mohan, {Sanjay R.} and Nadiminti, {Kalyan V.} and Stephen Oh and Animesh Pardanani and Nikolai Podoltsev and Lindsay Rein and Rachel Salit and Stein, {Brady L.} and Moshe Talpaz and Pankit Vachhani and Martha Wadleigh and Sarah Wall and Ward, {Dawn C.} and Bergman, {Mary Anne} and Cindy Hochstetler",

note = "Publisher Copyright: {\textcopyright} JNCCN.",

year = "2022",

month = sep,

doi = "10.6004/jnccn.2022.0046",

language = "English (US)",

volume = "20",

pages = "1033--1062",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "9",

}

TY - JOUR

T1 - Myeloproliferative Neoplasms, Version 3.2022

AU - Gerds, Aaron T.

AU - Gotlib, Jason

AU - Ali, Haris

AU - Bose, Prithviraj

AU - Dunbar, Andrew

AU - Elshoury, Amro

AU - George, Tracy I.

AU - Gundabolu, Krishna

AU - Hexner, Elizabeth

AU - Hobbs, Gabriela S.

AU - Jain, Tania

AU - Jamieson, Catriona

AU - Kaesberg, Paul R.

AU - Kuykendall, Andrew T.

AU - Madanat, Yazan

AU - McMahon, Brandon

AU - Mohan, Sanjay R.

AU - Nadiminti, Kalyan V.

AU - Oh, Stephen

AU - Pardanani, Animesh

AU - Podoltsev, Nikolai

AU - Rein, Lindsay

AU - Salit, Rachel

AU - Stein, Brady L.

AU - Talpaz, Moshe

AU - Vachhani, Pankit

AU - Wadleigh, Martha

AU - Wall, Sarah

AU - Ward, Dawn C.

AU - Bergman, Mary Anne

AU - Hochstetler, Cindy

PY - 2022/9

Y1 - 2022/9

N2 - The classic Philadelphia chromosome-negativemyeloproliferative neoplasms (MPN) consist ofmyelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for themanagement of MPN in adults. TheGuidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.

AB - The classic Philadelphia chromosome-negativemyeloproliferative neoplasms (MPN) consist ofmyelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for themanagement of MPN in adults. TheGuidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.

UR - http://www.scopus.com/inward/record.url?scp=85137545298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137545298&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2022.0046

DO - 10.6004/jnccn.2022.0046

M3 - Article

C2 - 36075392

AN - SCOPUS:85137545298

SN - 1540-1405

VL - 20

SP - 1033

EP - 1062

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 9

ER -

Myeloproliferative Neoplasms, Version 3.2022

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this